Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yuqing Xu, Meijing Wu, Weili He, Qiming Liao & Yabing Mai. (2022) Teasing Out the Overall Survival Benefit With Adjustment for Treatment Switching to Multiple Treatments. Statistics in Biopharmaceutical Research 14:4, pages 592-601.
Read now
Read now
Shogo Nomura, Tomohiro Shinozaki & Chikuma Hamada. (2020) Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials. Journal of Biopharmaceutical Statistics 30:2, pages 377-401.
Read now
Read now
Articles from other publishers (16)
P. Chen, M. Liu, G.Y. Li, F. Sun & T. Li. (2023) Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial. Annals of Oncology.
Crossref
Crossref
Marius Goldkuhle, Gordon H. Guyatt, Nina Kreuzberger, Elie A. Akl, Philipp Dahm, Elvira C. van Dalen, Lars G. Hemkens, Miloslav Klugar, Reem A. Mustafa, Francesco Nonino, Holger J. Schünemann, Marialene Trivella & Nicole Skoetz. (2023) GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targets. Journal of Clinical Epidemiology 159, pages 40-48.
Crossref
Crossref
Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, Michael R Bishop, Daniel S Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Robert L Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini & Mario Sznol. (2022) Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for ImmunoTherapy of Cancer 10:9, pages e005413.
Crossref
Crossref
Lilla Di Scala, Marisa Bacchi, Bjørn Bayer & Stefano Turricchia. (2022) Adjusting Overall Survival Estimates of Macitentan in Pulmonary Arterial Hypertension After Treatment Switching: Results from the SERAPHIN Study. Advances in Therapy 39:9, pages 4346-4358.
Crossref
Crossref
Felicitas Kuehne, Ursula Rochau, Noman Paracha, Jennifer M. Yeh, Eduardo Sabate & Uwe Siebert. (2021) Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling. Medical Decision Making 42:2, pages 194-207.
Crossref
Crossref
Juliane Manitz, Natalia Kan‐Dobrosky, Hannes Buchner, Marie‐Laure Casadebaig, Evgeny Degtyarev, Jyotirmoy Dey, Vincent Haddad, Fei Jie, Emily Martin, Mindy Mo, Kaspar Rufibach, Yue Shentu, Viktoriya Stalbovskaya, Rui (Sammi) Tang, Godwin Yung & Jiangxiu Zhou. (2021) Estimands for overall survival in clinical trials with treatment switching in oncology. Pharmaceutical Statistics 21:1, pages 150-162.
Crossref
Crossref
Rachel Evans, Neil Hawkins, Pascale Dequen-O’Byrne, Charles McCrea, Dominic Muston, Christopher Gresty, Sameer R. Ghate, Lin Fan, Robert Hettle, Keith R. Abrams, Johann de Bono, Maha Hussain & Neeraj Agarwal. (2021) Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology 16:5, pages 613-623.
Crossref
Crossref
Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, Rong Liu, Daniel Li & Michael LaValley. (2021) Critical review of oncology clinical trial design under non-proportional hazards. Critical Reviews in Oncology/Hematology 162, pages 103350.
Crossref
Crossref
Tushar Srivastava, Vimalanand S. Prabhu, Haojie Li, Ruifeng Xu, Natalie Zarabi, Yichen Zhong, James M. Pellissier, Rodolfo F. Perini, Ronald de Wit & Ronac Mamtani. (2020) Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. European Urology Oncology 3:5, pages 663-670.
Crossref
Crossref
Thomas R. Sullivan, Nicholas R. Latimer, Jodi Gray, Michael J. Sorich, Amy B. Salter & Jonathan Karnon. (2020) Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. Value in Health 23:3, pages 388-396.
Crossref
Crossref
Helen Bell Gorrod, Nicholas R. Latimer, Doris Damian, Robert Hettle, Gerard T. Harty & Schiffon L. Wong. (2019) Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods. Advances in Therapy 37:1, pages 225-239.
Crossref
Crossref
N. R. Latimer, K. R. Abrams & U. Siebert. (2019) Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring. BMC Medical Research Methodology 19:1.
Crossref
Crossref
Susan Feyerabend, Fred Saad, Nolen Joy Perualila, Suzy Van Sanden, Joris Diels, Tetsuro Ito, Peter De Porre & Karim Fizazi. (2019) Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study. Targeted Oncology 14:6, pages 681-688.
Crossref
Crossref
Helen Bell Gorrod, Nicholas R. Latimer, Doris Damian, Robert Hettle, Gerard T. Harty & Schiffon L. Wong. (2019) Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. Value in Health 22:7, pages 772-776.
Crossref
Crossref
Iain Bennett, Noman Paracha, Keith Abrams & Joshua Ray. (2018) Accounting for Uncertainty in Decision Analytic Models Using Rank Preserving Structural Failure Time Modeling: Application to Parametric Survival Models. Value in Health 21:1, pages 105-109.
Crossref
Crossref
Konstantina Skaltsa, Cristina Ivanescu, Shevani Naidoo, De Phung, Stefan Holmstrom & Nicholas R. Latimer. (2016) Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology 12:1, pages 111-121.
Crossref
Crossref